エーザイ、第17回アルツハイマー・パーキンソン病学会(AD/PD 2023)において、レカネマブの安全性プロファイル、臨床結果、QOLの評価など、アルツハイマー病の研究に関する最新情報を発表 Eisai Mar 23, 2023 09:00 JST Read More
Health-ISAC Releases Annual Report on Current and Emerging Cyber Threats to Healthcare Health-ISAC Mar 22, 2023 23:00 HKT/SGT Read More
Health-ISAC Releases Annual Report on Current and Emerging Cyber Threats to Healthcare Health-ISAC Mar 22, 2023 23:00 HKT/SGT Read More
With U.S. Health Systems Under Growing Pressure to Fill Staff Vacancies, CGFNS Alliance Releases Updated Standards for Ethical Recruitment of Foreign Health Workers CGFNS International Mar 21, 2023 19:00 HKT/SGT Read More
Singapore family cord blood bank Cryoviva upgrades to AXP II System for cord blood processing Cryoviva Singapore Mar 21, 2023 08:30 HKT/SGT Read More
Singapore family cord blood bank Cryoviva upgrades to AXP II System for cord blood processing Cryoviva Singapore Mar 21, 2023 08:00 HKT/SGT Read More
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal Eisai Mar 20, 2023 10:18 HKT/SGT Read More
エーザイ、臨床第III相 Clarity AD 試験データを用いた「レカネマブ」の社会的価値について、査読学術専門誌 Neurology and Therapy 誌に掲載 Eisai Mar 20, 2023 10:00 JST Read More
Avantor Named Best Bioprocessing Company in Chromatography at the Asia-Pacific Bioprocessing Excellence Awards Avantor Mar 16, 2023 09:00 HKT/SGT Read More
analytica Vietnam 2023: The Largest Gathering of Laboratory Technology, Analysis and Biotechnology Professionals in Southeast Asia MMI Asia Pte Ltd (MMI) Mar 16, 2023 08:00 HKT/SGT Read More
Prenetics公布2022年第四季度及全年财务业绩 新业务策略专注于精准肿瘤学 Prenetics Global Limited Mar 14, 2023 22:07 HKT/SGT Read More
Prenetics公布2022年第四季度及全年財務業績 新業務策略專注於精準腫瘤學 Prenetics Global Limited Mar 14, 2023 22:06 HKT/SGT Read More
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology Prenetics Global Limited Mar 14, 2023 22:05 HKT/SGT Read More
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease Eisai Mar 14, 2023 10:09 HKT/SGT Read More
エーザイ、早期アルツハイマー病治療薬「LEQEMBI(TM)」(レカネマブ)について、米国退役軍人保健局が FDA による迅速承認から 2 カ月で保険適用を開始 Eisai Mar 14, 2023 09:30 JST Read More